Agenus (AGEN)
(Delayed Data from NSDQ)
$15.60 USD
+0.21 (1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $15.61 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.60 USD
+0.21 (1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $15.61 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
by Zacks Equity Research
Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.
AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID
by Zacks Equity Research
CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.
Is Trending Stock Agenus Inc. (AGEN) a Buy Now?
by Zacks Equity Research
Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up
by Zacks Equity Research
J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.
Key Factors Driving Merck's (MRK) Outperformance This Year
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
by Zacks Equity Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up
by Zacks Equity Research
FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.
Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.
GSK's NDA for Daprodustat to be Reviewed by an FDA Panel
by Zacks Equity Research
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer
Is Most-Watched Stock Agenus Inc. (AGEN) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers
by Zacks Equity Research
Following FDA approval for label expansion, Vertex Pharmaceuticals' (VRTX) Orkambi is now approved for treating cystic fibrosis in children aged one year and older.
AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.
Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
by Zacks Equity Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss
by Zacks Equity Research
Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.
Community Health (CYH) Down 30.3% Since Q2 Earnings Report
by Zacks Equity Research
Community Health (CYH) expects capex to remain within $400-$450 million in 2022.
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 26.09% and 11.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.
Heska (HSKA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of -8.11% and 6.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View
by Zacks Equity Research
Centene (CNC) currently has $3.4 billion remaining in its share buyback program.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Agenus (AGEN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.